Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Hold” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average rating of “Hold” from the twenty-eight research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $27.7083.

Several research analysts have recently commented on the stock. Loop Capital set a $25.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Oppenheimer reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Wedbush lifted their price target on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 26th. Wells Fargo & Company reduced their target price on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. The trade was a 80.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aberdeen Group plc raised its position in shares of Sarepta Therapeutics by 59.6% during the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after buying an additional 740,360 shares in the last quarter. Boxer Capital Management LLC raised its position in shares of Sarepta Therapeutics by 900.0% during the 3rd quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock worth $4,818,000 after buying an additional 225,000 shares in the last quarter. Mirador Capital Partners LP bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $3,012,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Sarepta Therapeutics by 143.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after buying an additional 62,981 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Sarepta Therapeutics by 109.1% during the 3rd quarter. Principal Financial Group Inc. now owns 468,067 shares of the biotechnology company’s stock worth $9,020,000 after buying an additional 244,181 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $17.55 on Friday. The firm has a market cap of $1.85 billion, a P/E ratio of -18.28, a P/E/G ratio of 0.25 and a beta of 0.26. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $44.14. The firm has a fifty day moving average of $20.01 and a two-hundred day moving average of $20.16.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. During the same period in the previous year, the business posted ($3.42) EPS. The company’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, research analysts anticipate that Sarepta Therapeutics will post 3.1 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.